Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Vincristine 5Doxorubicin 5Cyclophosphamide 5Prednisone 4Peripheral Blood Stem Cell Transplantation 4Rituximab 3Ifosfamide 3Everolimus 3Etoposide 3Carboplatin 3romidepsin 2pembrolizumab 2fludarabine phosphate 2Whole-Body Irradiation 2Vorinostat 2Mycophenolic Acid 2Microarray Analysis 2Lenalidomide 2Immunohistochemistry 2Gene Expression Profiling 2Cyclosporine 2Clofarabine 210-propargyl-10-deazaaminopterin 2veliparib 1prednylidene 1liposomal doxorubicin 1indolepropanol phosphate 1flt3 ligand protein 1etoposide phosphate 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoblastic Lymphadenopathy × Lactones × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡